Jasmine Zain

16PUBLICATIONS
95CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyTransplantation immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Feb 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Joseph M Tuscano, Tamer Othman, Paul Frankel

|Nov 10, 2025
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Joseph M Tuscano, Tamer Othman, Paul Frankel

|Feb 14, 2025
Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma.

Christiane Querfeld, Joycelynne Palmer, Zhen Han

|Jun 05, 2024
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.

Jasmine Zain, Ni-Chun Tsai, Joycelynne Palmer

|May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.

Rahul S Bhansali, Fredrik Ellin, Thomas Relander

|Feb 02, 2024
Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.

Shin Yeu Ong, Jasmine M Zain

Pageof 3

Frequent Collaborators

4 joint publications

Francine M Foss

4 joint publications

Lihua Elizabeth Budde

3 joint publications

Alex F Herrera

2 joint publications

D Lynne Smith